Vivo Ventures Fund Vii, L.p. - Net Worth and Insider Trading

Vivo Ventures Fund Vii, L.p. Net Worth

The estimated net worth of Vivo Ventures Fund Vii, L.p. is at least $10.7 Billion dollars as of 2024-11-13. Vivo Ventures Fund Vii, L.p. is the 10% Owner of American Express Co and owns about 36,984,282 shares of American Express Co (AXP) stock worth over $10.7 Billion. Vivo Ventures Fund Vii, L.p. is the 10% Owner of Codexis Inc and owns about 5,294,825 shares of Codexis Inc (CDXS) stock worth over $21 Million. Vivo Ventures Fund Vii, L.p. is also the 10% Owner of Aclaris Therapeutics Inc and owns about 2,858,569 shares of Aclaris Therapeutics Inc (ACRS) stock worth over $7 Million. Details can be seen in Vivo Ventures Fund Vii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Vivo Ventures Fund Vii, L.p. has not made any transactions after 2018-08-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Vivo Ventures Fund Vii, L.p.

To

Vivo Ventures Fund Vii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Vivo Ventures Fund Vii, L.p. owns 4 companies in total, including Sierra Oncology Inc (SRRA) , Codexis Inc (CDXS) , and Aclaris Therapeutics Inc (ACRS) among others .

Click here to see the complete history of Vivo Ventures Fund Vii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Vivo Ventures Fund Vii, L.p.

Ticker Comapny Transaction Date Type of Owner
SRRA Sierra Oncology Inc 2015-07-15 10 percent owner
CDXS Codexis Inc 2016-09-08 10 percent owner
ACRS Aclaris Therapeutics Inc 2017-03-02 10 percent owner
LIMIT LIMIT 2012-12-18 10 percent owner

Vivo Ventures Fund Vii, L.p. Latest Holdings Summary

Vivo Ventures Fund Vii, L.p. currently owns a total of 3 stocks. Among these stocks, Vivo Ventures Fund Vii, L.p. owns 36,984,282 shares of American Express Co (AXP) as of August 30, 2018, with a value of $10.7 Billion and a weighting of 99.73%. Vivo Ventures Fund Vii, L.p. owns 5,294,825 shares of Codexis Inc (CDXS) as of September 8, 2016, with a value of $21 Million and a weighting of 0.2%. Vivo Ventures Fund Vii, L.p. also owns 2,858,569 shares of Aclaris Therapeutics Inc (ACRS) as of March 2, 2017, with a value of $7 Million and a weighting of 0.07%.

Latest Holdings of Vivo Ventures Fund Vii, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AXP American Express Co 2018-08-30 36,984,282 288.51 10,670,335,200
CDXS Codexis Inc 2016-09-08 5,294,825 4.03 21,338,145
ACRS Aclaris Therapeutics Inc 2017-03-02 2,858,569 2.55 7,289,351

Holding Weightings of Vivo Ventures Fund Vii, L.p.


Vivo Ventures Fund Vii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Vivo Ventures Fund Vii, L.p. has made a total of 0 transactions in American Express Co (AXP) over the past 5 years. The most-recent trade in American Express Co is the acquisition of 20,142,123 shares on August 30, 2018, which cost Vivo Ventures Fund Vii, L.p. around $3 Million.

According to the SEC Form 4 filings, Vivo Ventures Fund Vii, L.p. has made a total of 0 transactions in Codexis Inc (CDXS) over the past 5 years. The most-recent trade in Codexis Inc is the sale of 111,600 shares on September 8, 2016, which brought Vivo Ventures Fund Vii, L.p. around $474,300.

According to the SEC Form 4 filings, Vivo Ventures Fund Vii, L.p. has made a total of 0 transactions in Aclaris Therapeutics Inc (ACRS) over the past 5 years. The most-recent trade in Aclaris Therapeutics Inc is the sale of 425,000 shares on March 2, 2017, which brought Vivo Ventures Fund Vii, L.p. around $13 Million.

Insider Trading History of Vivo Ventures Fund Vii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Vivo Ventures Fund Vii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Vivo Ventures Fund Vii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Ventures Fund Vii, L.p. is 5.69%. GuruFocus also compares Vivo Ventures Fund Vii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Ventures Fund Vii, L.p. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Vivo Ventures Fund Vii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Vivo Ventures Fund Vii, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0.24 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -0.2 LIMIT LIMIT LIMIT LIMIT LIMIT

Vivo Ventures Fund Vii, L.p. Ownership Network

Ownership Network List of Vivo Ventures Fund Vii, L.p.

No Data

Ownership Network Relation of Vivo Ventures Fund Vii, L.p.

Insider Network Chart

Vivo Ventures Fund Vii, L.p. Owned Company Details

What does Sierra Oncology Inc do?

Who are the key executives at Sierra Oncology Inc?

Vivo Ventures Fund Vii, L.p. is the 10 percent owner of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .

Sierra Oncology Inc (SRRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Sierra Oncology Inc Insider Transactions

No Available Data

Vivo Ventures Fund Vii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Vivo Ventures Fund Vii, L.p.. You might contact Vivo Ventures Fund Vii, L.p. via mailing address: 505 Hamilton Avenue, Suite 200, Palo Alto Ca 94301.